FDA Action Alert: Argenx, Aldeyra, Intercept and Sarepta

The FDA is set to make four important decisions this week, including the approval of Argenx’s subcutaneous efgartigimod for adults with generalized myasthenia gravis, Aldeyra’s investigational intravitreal injection ADX-2191 for primary vitreoretinal lymphoma, Intercept Pharmaceuticals’ obeticholic acid for pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis, and Sarepta’s gene the..